Weight Loss Peptides: GLP-1 Agonists & Research Compounds
The weight loss peptide category contains the most clinically validated compounds in the entire peptide space. FDA-approved GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have demonstrated sustained weight reduction of 15-25% in large randomized controlled trials. This category also includes investigational compounds like retatrutide, a triple-agonist currently in Phase 3 trials.
4 compounds in this category
SemaglutideOzempic, Wegovy
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.
TirzepatideMounjaro, Zepbound
An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.
AOD-9604Advanced Obesity Drug 9604, Anti-Obesity Drug 9604
A modified fragment of human growth hormone studied for fat metabolism without the growth-promoting effects of full GH.
RetatrutideLY3437943, Triple Agonist
A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.